Poxviridae Infections - Pipeline Review, H2 2016

Published: Aug, 2016 | Pages: 96 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Poxviridae Infections - Pipeline Review, H2 2016

Summary

Global Markets Direct's, 'Poxviridae Infections - Pipeline Review, H2 2016', provides an overview of the Poxviridae Infections pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Poxviridae Infections , complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Poxviridae Infections and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Poxviridae Infections 
- The report reviews pipeline therapeutics for Poxviridae Infections by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Poxviridae Infections therapeutics and enlists all their major and minor projects
- The report assesses Poxviridae Infections therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Poxviridae Infections 

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Poxviridae Infections 
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Poxviridae Infections pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Poxviridae Infections Overview 9
Therapeutics Development 10
Pipeline Products for Poxviridae Infections - Overview 10
Pipeline Products for Poxviridae Infections - Comparative Analysis 11
Poxviridae Infections - Therapeutics under Development by Companies 12
Poxviridae Infections - Therapeutics under Investigation by Universities/Institutes 14
Poxviridae Infections - Pipeline Products Glance 15
Late Stage Products 15
Early Stage Products 16
Poxviridae Infections - Products under Development by Companies 17
Poxviridae Infections - Products under Investigation by Universities/Institutes 18
Poxviridae Infections - Companies Involved in Therapeutics Development 19
Bavarian Nordic A/S 19
BioFactura, Inc. 20
CEL-SCI Corporation 21
Chimerix, Inc. 22
China Biologic Products, Inc. 23
CJ HealthCare Corp. 24
EpiVax, Inc. 25
N & N Pharmaceuticals Inc. 26
SIGA Technologies, Inc. 27
Takeda Pharmaceutical Company Limited 28
Tonix Pharmaceuticals Holding Corp. 29
Verrica Pharmaceuticals Inc. 30
Poxviridae Infections - Therapeutics Assessment 31
Assessment by Monotherapy Products 31
Assessment by Combination Products 32
Assessment by Target 33
Assessment by Mechanism of Action 35
Assessment by Route of Administration 37
Assessment by Molecule Type 39
Drug Profiles 41
(plague + small pox) vaccine - Drug Profile 41
Product Description 41
Mechanism Of Action 41
R&D Progress 41
24a - Drug Profile 42
Product Description 42
Mechanism Of Action 42
R&D Progress 42
BA-368 - Drug Profile 43
Product Description 43
Mechanism Of Action 43
R&D Progress 43
brincidofovir - Drug Profile 44
Product Description 44
Mechanism Of Action 44
R&D Progress 44
CEL-1000 - Drug Profile 57
Product Description 57
Mechanism Of Action 57
R&D Progress 57
CJ-40011 - Drug Profile 59
Product Description 59
Mechanism Of Action 59
R&D Progress 59
imatinib mesylate - Drug Profile 60
Product Description 60
Mechanism Of Action 60
R&D Progress 60
Monoclonal Antibodies for Infectious Disease - Drug Profile 61
Product Description 61
Mechanism Of Action 61
R&D Progress 61
Monoclonal Antibody for Smallpox - Drug Profile 62
Product Description 62
Mechanism Of Action 62
R&D Progress 62
nilotinib - Drug Profile 63
Product Description 63
Mechanism Of Action 63
R&D Progress 63
NN-001 - Drug Profile 64
Product Description 64
Mechanism Of Action 64
R&D Progress 64
PL-801 - Drug Profile 65
Product Description 65
Mechanism Of Action 65
R&D Progress 65
SCV-305 - Drug Profile 66
Product Description 66
Mechanism Of Action 66
R&D Progress 66
Small Molecules for Molluscum Contagiosum - Drug Profile 67
Product Description 67
Mechanism Of Action 67
R&D Progress 67
small pox vaccine - Drug Profile 68
Product Description 68
Mechanism Of Action 68
R&D Progress 68
smallpox vaccine - Drug Profile 69
Product Description 69
Mechanism Of Action 69
R&D Progress 69
smallpox vaccine - Drug Profile 73
Product Description 73
Mechanism Of Action 73
R&D Progress 73
tecovirimat - Drug Profile 74
Product Description 74
Mechanism Of Action 74
R&D Progress 74
varicella hyperimmune globulins - Drug Profile 79
Product Description 79
Mechanism Of Action 79
R&D Progress 79
VIR-001 - Drug Profile 80
Product Description 80
Mechanism Of Action 80
R&D Progress 80
VIR-002 - Drug Profile 81
Product Description 81
Mechanism Of Action 81
R&D Progress 81
VP-100 - Drug Profile 82
Product Description 82
Mechanism Of Action 82
R&D Progress 82
Poxviridae Infections - Dormant Projects 83
Poxviridae Infections - Discontinued Products 86
Poxviridae Infections - Product Development Milestones 87
Featured News & Press Releases 87
Jun 15, 2016: Bavarian Nordic Announces Expansion of IMVAMUNE Orders from Canadian Government 87
Apr 25, 2016: SIGA Announces Enrollment of First Patients in the Final Cohort of Phase III Study of Tecovirimat 87
Mar 17, 2016: SIGA Commences Clinical Study for Intravenous (IV) Formulation of TPOXX 87
Feb 24, 2016: FDA Concurs on Clinical Dose for SIGA's Tecovirimat Antiviral 88
Feb 24, 2016: FDA Concurs on Clinical Dose for SIGA's Tecovirimat Antiviral 88
Feb 08, 2016: Chimerix Presents Positive Results From Brincidofovir Pivotal Study in Animal Model for Smallpox 88
Dec 24, 2015: Delaware Supreme Court Affirms Chancery Court Ruling in Favor of PharmAthene 89
Sep 14, 2015: Chimerix and BARDA Announce Contract Extension of $13.0 Million for the Continued Development of Brincidofovir for Smallpox 89
Jul 23, 2015: Chimerix Announces Positive Topline Results From Brincidofovir Pivotal Study in Animal Model for Smallpox 90
Jul 07, 2015: Bavarian Nordic Receives Order for IMVAMUNE Smallpox Vaccine from the U.S. Government Valued at USD 133 Million 90
May 13, 2015: Bavarian Nordic Announces Positive Results from Two Pivotal Clinical Studies of IMVAMUNE Smallpox Vaccine 91
Jan 16, 2015: SIGA Technologies Appeals Judgment of Delaware Court of Chancery 92
Jan 07, 2015: Delaware Court of Chancery Issues Order Specifying Amount Of Lump Sum Expectation Damages Payable To PharmAthene; Total Award When Finalized, Including Pre-Judgment Interest, Attorneys' And Expert Witness Fees, Estimated To Be In Excess Of $190 Million 92
Dec 23, 2014: Chimerix Provides Recap of 2014 Events 93
Oct 04, 2014: Bavarian Nordic Announces Exercise of Contract Option by the U.S. Government for Continued Supply of IMVAMUNE Smallpox Vaccine 94
Appendix 95
Methodology 95
Coverage 95
Secondary Research 95
Primary Research 95
Expert Panel Validation 95
Contact Us 95
Disclaimer 96

List of Tables

Number of Products under Development for Poxviridae Infections, H2 2016 10
Number of Products under Development for Poxviridae Infections - Comparative Analysis, H2 2016 11
Number of Products under Development by Companies, H2 2016 13
Number of Products under Investigation by Universities/Institutes, H2 2016 14
Comparative Analysis by Late Stage Development, H2 2016 15
Comparative Analysis by Early Stage Development, H2 2016 16
Products under Development by Companies, H2 2016 17
Products under Investigation by Universities/Institutes, H2 2016 18
Poxviridae Infections - Pipeline by Bavarian Nordic A/S, H2 2016 19
Poxviridae Infections - Pipeline by BioFactura, Inc., H2 2016 20
Poxviridae Infections - Pipeline by CEL-SCI Corporation, H2 2016 21
Poxviridae Infections - Pipeline by Chimerix, Inc., H2 2016 22
Poxviridae Infections - Pipeline by China Biologic Products, Inc., H2 2016 23
Poxviridae Infections - Pipeline by CJ HealthCare Corp., H2 2016 24
Poxviridae Infections - Pipeline by EpiVax, Inc., H2 2016 25
Poxviridae Infections - Pipeline by N & N Pharmaceuticals Inc., H2 2016 26
Poxviridae Infections - Pipeline by SIGA Technologies, Inc., H2 2016 27
Poxviridae Infections - Pipeline by Takeda Pharmaceutical Company Limited, H2 2016 28
Poxviridae Infections - Pipeline by Tonix Pharmaceuticals Holding Corp., H2 2016 29
Poxviridae Infections - Pipeline by Verrica Pharmaceuticals Inc., H2 2016 30
Assessment by Monotherapy Products, H2 2016 31
Assessment by Combination Products, H2 2016 32
Number of Products by Stage and Target, H2 2016 34
Number of Products by Stage and Mechanism of Action, H2 2016 36
Number of Products by Stage and Route of Administration, H2 2016 38
Number of Products by Stage and Molecule Type, H2 2016 40
Poxviridae Infections - Dormant Projects, H2 2016 83
Poxviridae Infections - Dormant Projects (Contd..1), H2 2016 84
Poxviridae Infections - Dormant Projects (Contd..2), H2 2016 85
Poxviridae Infections - Discontinued Products, H2 2016 86